» Articles » PMID: 17504213

Interferon: Cellular Executioner or White Knight?

Overview
Journal Curr Med Chem
Specialty Chemistry
Date 2007 May 17
PMID 17504213
Citations 71
Authors
Affiliations
Soon will be listed here.
Abstract

Interferons (IFNs) are a family of pleiotropic cytokines that typically exhibit antiviral, antiproliferative, antitumor, and immunomodulatory properties. While their complex mechanisms of action remain unclear, IFNs are used clinically in the treatment of viral infections, such as hepatitis B and hepatitis C, and remain the primary treatment for a limited number of malignancies, such as melanoma, hairy cell leukemia, and non-Hodgkin's lymphoma and in autoimmune diseases such as multiple sclerosis. IFNs not only regulate somatic cell growth and division but also influence cell survival through the modulation of apoptosis. Paradoxically, IFNs are described to be both pro- and anti-apoptotic in nature. The biological effects of IFNs are primarily mediated via activation of the JAK/STAT pathway, formation of the ISGF3 and STAT1:STAT1 protein complexes, and the subsequent induction of IFN-stimulated genes. However, the activation of JAK/STAT-independent signal transduction pathways also contribute to IFN-mediated responses. To further demonstrate the complexity of the downstream events following stimulation, oligonucleotide microarray studies have shown that in excess of 300 genes are induced following treatment with IFN, some of which are crucial to the induction of apoptosis and cell growth control. In this review we describe the recent advances made in elucidating the various signaling pathways that are activated by IFNs and how these diverse signals contribute to the regulation of cell growth and apoptosis and inhibition of viral replication. Furthermore, we highlight the role of specific signaling molecules and the function(s) of particular IFN-stimulated genes that have been implicated in determining cell fate in response to IFN, as well as the clinical experience of IFN immunotherapy.

Citing Articles

FAM210B activates STAT1/IRF9/IFIT3 axis by upregulating IFN-α/β expression to impede the progression of lung adenocarcinoma.

Gao X, Huang D, Liu Y, Zhang G, Zheng X, Guan B Cell Death Dis. 2025; 16(1):63.

PMID: 39900908 PMC: 11791038. DOI: 10.1038/s41419-025-07375-9.


Type I interferon signaling induces a delayed antiproliferative response in respiratory epithelial cells during SARS-CoV-2 infection.

Bragazzi Cunha J, Leix K, Sherman E, Mirabelli C, Frum T, Zhang C J Virol. 2023; 97(12):e0127623.

PMID: 37975674 PMC: 10734423. DOI: 10.1128/jvi.01276-23.


Adjuvant Temozolomide Chemotherapy With or Without Interferon Alfa Among Patients With Newly Diagnosed High-grade Gliomas: A Randomized Clinical Trial.

Guo C, Yang Q, Xu P, Deng M, Jiang T, Cai L JAMA Netw Open. 2023; 6(1):e2253285.

PMID: 36705923 PMC: 11839150. DOI: 10.1001/jamanetworkopen.2022.53285.


The duality of STAT2 mediated type I interferon signaling in the tumor microenvironment and chemoresistance.

Canar J, Darling K, Dadey R, Gamero A Cytokine. 2022; 161:156081.

PMID: 36327541 PMC: 9720715. DOI: 10.1016/j.cyto.2022.156081.


IFI44 is an immune evasion biomarker for SARS-CoV-2 and infection in patients with RA.

Zheng Q, Wang D, Lin R, Lv Q, Wang W Front Immunol. 2022; 13:1013322.

PMID: 36189314 PMC: 9520788. DOI: 10.3389/fimmu.2022.1013322.